Skip to main content

Improving patient outcomes with innovative diagnostics for
critical care: Actionable insights in real-time

Discover our Biomarker Solutions

09.09.2021 | SphingoTec’s innovative biomarkers to enable personalized medicine in septic organ failure Read more

31.08.2021 | New data on innovative biomarkers used to guide the clinical management of septic patients Read more

23.08.2021 | SphingoTec Appoints Dr. Gerald Möller as Chairman of the Advisory Board Read more

10.06.2021 | SphingoTec Expands Management Team and Appoints new CFO Read more

31.05.2021 | SphingoTec in the news: Private Wealth cover story "If I don't do it, nobody will” Read more

20.05.2021 | SphingoTec Accelerates Growth with Direct Sales Read more

04.05.2021 | Endothelial Function Biomarker bio-ADM to Support Risk Stratification and Clinical Management of COVID-19 Patients Read more

23.03.2021 | New diagnostic tool for the management of patients with sepsis: Dipeptidyl Peptidase 3 (DPP3) Read more

18.02.2021 | Two distinct pathways leading to the development of septic shock pave the way for personalized medicine in sepsis Read more

The Biomarker Company

SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers for the diagnosis, outcome prediction, and monitoring of critical medical conditions.

SphingoTec’s first-in-class biomarker tests are made available on its proprietary whole-blood point-of-care Nexus IB10 platform for convenient and rapid testing in near-patient and laboratory settings alongside a broad portfolio of standard-of-care test for critical care. For high-throughput testing in central laboratories, SphingoTec partners with global IVD players. 

EU & US BASED

SphingoTec is headquartered near Berlin, Germany while its wholly owned subsidiary Nexus Dx is based in San Diego, CA, USA.

IP PROTECTION

All of SphingoTec's biomarkers are globally patent protected

COMMERCIAL PLATFORM

Diagnostic assays for SphingoTec‘s biomarkers are available on its proprietary fully developed and commercialized  POC platform Nexus IB10

CLINICAL DEVELOPMENT

SphingoTec’s biomarkers are broadly validated and published in peer-reviewed journals

DIAGNOSTIC SOLUTIONS

In collaboration with an international network of key opinion leaders, SphingoTec develops solutions for fighting mortality in critical care conditions

KNOW-HOW

SphingoTec’s management builds on an extraordinary track-record in R&D and commercialization of novel diagnostic solutions

Innovative acute care biomarkers

Following a deep understanding of disease biology, SphingoTec developes novel biomarkers addressing diagnostically underserved critical care conditions such sepsis, acute heart failure, acute kidney injury, and cardiogenic shock

Discover more

Point-of-care testing with Nexus IB10 Analyzer

The CE-IVD marked Nexus IB10 platform is a fully automated rapid immunoassay point-of-care instrument. With a hands-on-time of less than 3 minutes the easy-to-use system provides in only 20 minutes test results for biomarkers that are crucial in the management of critical care patients.

Discover more


Acute Care Pathways

Sepsis

Diagnostic tools in Sepsis

Recent research has identified new molecules that are informative and help clinicians understand the etiology of the patient’s clinical symptoms, paving the way for personalized medicine in the field of sepsis.

COVID-19

Biomarkers and the management of COVID-19 patients 

The global COVID-19 pandemic has challenged health systems world-wide, with about 5% of patients requiring admission to intensive care units (ICU). Read more on the importance of novel and established biomarker assays in the management of critically ill COVID-19 patients.

Latest News

09. September 2021
SphingoTec announces a series of presentations demonstrating the utility of its innovative biomarkers in sepsis, positively impacting diagnostic and treatment decisions for critically ill patients.
Read more
31. August 2021
Uniklinik RWTH Aachen and SphingoTec GmbH announce today that novel data on the acute care biomarkers bio-ADM and penKid will be presented at the 40th ISICEM.
Read more
23. August 2021
Diagnostics company SphingoTec GmbH announces that Dr. Gerald Möller has joined the company’s advisory board as chairman of the board.
Read more

Events & Expos

23. - 26. September 2021

09:31 - 09:33

Rostock, DE
The Forum Nephrologie is a scientific, educational, and networking meeting and part of the 13. Jahrestagung der DGfN. The main congress program will kick off with an opening ceremony on Thursday, followed by 2,5 days of scientific activity.
Read more
08. - 10. September 2021

08:49 - 08:50

Weimar, DE
The 10th Sepsis Update with the theme “Beyond the pandemic“ will take place from 8th to 10th September 2021. 
Read more
31. August - 03. September 2021

11:00 - 20:00

Brussels, Belgium
This year is the 40th edition of the ISICEM congress in Brussels and we are delighted to once again be exhibiting.
Read more

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Follow our Journey on Social Media